Adverse events of fluoxetine: postmarketing compared with premarketing clinical trials
Musa, M.N.; Staneluis, J.M.
Journal of Clinical Psychiatry 61(11): 874
2000
ISSN/ISBN: 0160-6689 PMID: 11105745 Document Number: 514669
Document emailed within 1 workday
Related Documents
Beasley, C.M.; Nilsson, M.E.; Koke, S.C.; Gonzales, J.S. 2000: Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose Journal of Clinical Psychiatry 61(10): 722-728Hemmingsen, B.; Støy, L.; Wetterslev, Jørn.; Tarnow, L.; Friis, K.Bach.; Christensen, L.Lundby.; Sales, N.; Gluud, C.; Madsbad, S.; Snorgaard, O.; Røder, M.; Thorsteinsson, B.; Gade-Rasmussen, B.; Jarløv, A.; Sneppen, S.; Duun, E.; Jensen, T.; Mathiesen, E.; Perrild, H.; Krarup, T.; Vestergaard, H.; Nielsen, F.; Hedetoft, C.; Breum, L.; Christensen, L.Lundby.; Lund, Søren.S.; Boesgaard, T.W.; Tarnow, L.; Pedersen, O.; Vaag, A.; Almdal, T.; Hemmingsen, B.; Wetterslev, Jørn.; Gluud, C.; Hansen, B.Visbøll.; Rosenfeldt, M.; Salas, N. 2010: Reporting adverse reactions and events in randomised clinical trials Ugeskrift for Laeger 172(35): 2381-2384
Lutfullin, A.; Kuhlmann, J.; Wensing, G. 2005: Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1,559 subjects International Journal of Clinical Pharmacology and Therapeutics 43(5): 217-226
Welch, V.; Singh, G.; Strand, V.; Fries, J.; Boers, M.; Ramey, D.; Day, R.O.; Brooks, P.; Tugwell, P.; Clinch, J.; Kristjansson, B. 2001: Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index Journal of Rheumatology 28(5): 1188-1191
Lassere, M.N.D.; Johnson, K.R.; Boers, M.; Carlton, K.; Day, R.O.; de Wit, M.; Edwards, I.Ralph.; Fries, J.F.; Furst, D.E.; Kirwan, J.R.; Tugwell, P.S.; Woodworth, T.G.; Brooks, P.M. 2005: Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update Journal of Rheumatology 32(10): 2037-2041
Menter, A.; Reich, K.; Gottlieb, A.B.; Bala, M.; Li, S.; Hsu, M-Chun.; Guzzo, C.; Diels, J.; Gelfand, J.M. 2008: Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations Journal of Drugs in Dermatology: Jdd 7(12): 1137-1146
Ferry, L.; Johnston, J.A. 2003: Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience International Journal of Clinical Practice 57(3): 224-230
Bezruchka, S. 2001: Adverse events in British hospitals. Expanded definition of adverse events is needed Bmj 322(7299): 1427
Kodama, Y. 2009: Institutional investigations on clinical adverse events Kyobu Geka. Japanese Journal of Thoracic Surgery 62(2): 145-148
Homma, M. 1992: Adverse events and adverse reactions associated with drugs--important actual spontaneous reporting of the drug event Ryumachi 32(5): 429-431
Jozic, J.; Orford, J.; Steinhubl, S.; Berger, P.; Hsu, A.; Topol, E. 2008: Timing and correlates of very early major adverse clinical events following percutaneous coronary intervention Journal of Invasive Cardiology 20(3): 113-118
Gaebel, J.; Kolter, T.; Arlt, F.; Denecke, K. 2015: Extraction Of Adverse Events From Clinical Documents To Support Decision Making Using Semantic Preprocessing Studies in Health Technology and Informatics 216: 1030
Krummenauer, F. 2017: Multiple endpoints in clinical trials – severe adverse event potentials from the medical biometrician's perspective Medizinische Monatsschrift für Pharmazeuten 40(5): 209-213
Richter, J.M.; Colditz, G.A.; Huse, D.M.; Delea, T.E.; Oster, G. 1989: Cimetidine and adverse reactions: a meta-analysis of randomized clinical trials of short-term therapy American Journal of Medicine 87(3): 278-284
Richman, D.; Itri, L.; Johnson, M.F.; Eigo, J. 1990: Methodological issues in AIDS clinical trials. Discussion. Design of clinical trials--active control (equivalence) trials Journal of Acquired Immune Deficiency Syndromes 3 Suppl. 2: S88
Turon-Estrada, A.; López-Pousa, S.; Gelada-Batlle, E.; Garre-Olmo, J.; Lozano-Gallego, M.; Hernández-Ferràndiz, M.; Fajardo-Tibau, C.; Morante-Muñoz, V.; Vilalta-Franch, J. 2003: Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period Revista de Neurologia 36(5): 421-424
Kongsakon, R.; Bunchapattanasakda, C. 2008: The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation Journal of the Medical Association of Thailand 91(7): 1117-1128
Pacher, P.; Ungvari, Z.; Kecskemeti, V.; Furst, S. 1998: Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants Current Medicinal Chemistry 5(5): 381-390
Lietman, P.; Temple, R.; Harrington, M.; Peck, C. 1990: Methodological issues in AIDS clinical trials. Discussion. Design of clinical trials--approaches to clinical trials design Journal of Acquired Immune Deficiency Syndromes 3 Suppl. 2: S27
Patterson, C. 1999: Postmarketing surveillance study of a non-chlorofluorocarbon inhaler Postmarketing surveillance studies remain unethical Bmj 318(7186): 810-811